# Immune Modulators for Treating COVID-19

> **NCT04593940** · PHASE3 · COMPLETED · sponsor: **Daniel Benjamin** · enrollment: 1971 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Abatacept
- **DRUG:** Remdesivir
- **DRUG:** cenicriviroc (closed to enrollment as of 3-Sep-2021)

## Key facts

- **NCT ID:** NCT04593940
- **Lead sponsor:** Daniel Benjamin
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-15
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-03-05
- **Target enrollment:** 1971 (ACTUAL)
- **Last updated:** 2023-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04593940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04593940, "Immune Modulators for Treating COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04593940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*